LitCovid-sentences  

PMC:7696151 / 119717-123655 JSONTXT 3 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T793 0-72 Sentence denotes Table 2 Main mechanisms of action underlying biological effects of HCQ.
T794 73-142 Sentence denotes Disease Experimental Model Dosage Mechanisms of Action References
T795 143-245 Sentence denotes Rheumatoid arthritis (RA) Preclinical 40 mg/kg/day ↓neutrophil-derived oxidants ↓inflammation [75]
T796 246-340 Sentence denotes Clinical (randomized double-blind, placebo-controlled trial) 7 mg/kg/day ↓inflammation [76]
T797 341-433 Sentence denotes Clinical (comparative randomized double-blind trial) 200–400 mg/day ↓inflammation [77,78]
T798 434-523 Sentence denotes RA-associated cardiovascular disease Clinical n.a. ↓IL-6 and leptin↓dyslipidemia [79]
T799 524-605 Sentence denotes Clinical (cohort study) 6.5 mg/kg/day ↓triglycerides and LDL↓dyslipidemia [80]
T800 606-713 Sentence denotes Clinical (randomized double-blind cross-over trial) 6.5 mg/kg/day ↓cholesterol and LDL↓dyslipidemia [81]
T801 714-799 Sentence denotes Clinical (cross-sectional observational study) 200 mg/kg/day ↓fasting glucose [82]
T802 800-957 Sentence denotes Systemic lupus erythematosus (SLE) Clinical (randomized double-blind placebo-controlled trial) 100–400 mg/kg/day ↓inflammation↓risk of exacerbations [83]
T803 958-1050 Sentence denotes Clinical (long-term randomized study) 272 mg/day ↓inflammation↓risk of exacerbations [84]
T804 1051-1126 Sentence denotes Clinical (case-control study) 6.5 mg/kg/day ↓inflammation↑ survival [85]
T805 1127-1207 Sentence denotes Preclinical 100 mg/kg/day ↓Th17 response ↑Treg immunosuppressive effects [86]
T806 1208-1284 Sentence denotes Clinical (prospective cohort study) 400 mg/day ↓inflammatory markers [87]
T807 1285-1337 Sentence denotes Clinical (multiethnic US cohort) n.a. ↓IFN-α [88]
T808 1338-1398 Sentence denotes Preclinical 4–40 mg/kg/day ↓ mast cells↓ skin lesion [89]
T809 1399-1494 Sentence denotes SLE-associated cardiovascular disease Preclinical 10 mg/kg/day ↓ROS↓endothelial damage [90]
T810 1495-1568 Sentence denotes Preclinical 3 mg/kg/day ↓ROS and nitric oxide↓ endothelial damage [91]
T811 1569-1619 Sentence denotes Clinical 400 mg/day ↓triglycerides and LDL [92]
T812 1620-1689 Sentence denotes Clinical (cross-sectional study) 400 mg/day ↓ fasting glucose [82]
T813 1690-1791 Sentence denotes SLE-associated pregnancy complications Clinical (randomized double-blind) n.a. ↓inflammation [93]
T814 1792-1878 Sentence denotes Clinical (prospective study) 6.5 mg/kg/day ↓inflammation↓risk of exacerbations [94]
T815 1879-1996 Sentence denotes Antiphospholipid syndrome Preclinical 200 μg/day ↓inflammation↓complement activation↓placental abnormalities [95]
T816 1997-2059 Sentence denotes Clinical (case report) 400 mg/day ↓vascular thrombosis [96]
T817 2060-2134 Sentence denotes Preclinical 12 μg/g/day ↓endothelial damage ↓nitric oxide synthase [97]
T818 2135-2210 Sentence denotes Preclinical 20 mg/kg/day ↓endothelial damage ↓nitric oxide synthase [98]
T819 2211-2334 Sentence denotes Clinical (observational prospective study) 200 mg/day ↓thrombotic events in patients ↓soluble tissue factor levels. [99]
T820 2335-2408 Sentence denotes Sjögren syndrome Clinical 200 mg/day ↓inflammation ↓IgG and IgA [100]
T821 2409-2469 Sentence denotes Clinical (prospective study) 400 mg/day ↓xerostomia [101]
T822 2470-2530 Sentence denotes Clinical (prospective study) 6.5 mg/kg ↓eye dryness [102]
T823 2531-2598 Sentence denotes Preclinical 50 mg/kg/day ↓ xerostomia ↓ TGF-β↓inflammation [103]
T824 2599-2671 Sentence denotes Preclinical 60 mg/kg/day ↓inflammation↓lymphocytic infiltration [104]
T825 2672-2738 Sentence denotes Diabetes Preclinical 80–120–160 mg/kg/day ↓blood glucose [105]
T826 2739-2813 Sentence denotes Preclinical 200 mg/kg/day ↓inflammatory markers↑metabolic profile [106]
T827 2814-2901 Sentence denotes Clinical (randomized, double-blinded study) 2 × 300 mg/kg ↓glycated hemoglobin [107]
T828 2902-2985 Sentence denotes Clinical (open-label longitudinal study) 6.5 mg/kg/day ↓insulin resistance [108]
T829 2986-3083 Sentence denotes Clinical (randomized, double-blinded controlled trial) 6.5 mg/kg/day ↓insulin resistance [109]
T830 3084-3177 Sentence denotes Clinical (randomized, double-blinded trial) 400 mg/day ↑glycemic and lipidic profile [110]
T831 3178-3274 Sentence denotes Cancer Preclinical 50 mg/kg ↓tumor size↓pro-tumorigenic and pro-inflammatory cytokines [111]
T832 3275-3359 Sentence denotes Cardiovascular diseases Preclinical 200 mg/kg ↓apoptosis in cardiomyocites [112]
T833 3360-3417 Sentence denotes Preclinical 200 mg/kg/day ↓triglycerides and LDL [113]
T834 3418-3481 Sentence denotes Preclinical 10 mg/kg/day ↓atherosclerosis↓inflammation [114]
T835 3482-3564 Sentence denotes Inflammatory bowel disease and colitis Preclinical 30 mg/kg ↓inflammation [74]
T836 3565-3636 Sentence denotes Pulmonary hypertension Preclinical 50 mg/kg/day ↓inflammation [115]
T837 3637-3709 Sentence denotes Endometriosis Preclinical 60 mg/kg ↓inflammation↓lesion number [116]
T838 3710-3938 Sentence denotes LDL: low-density lipoproteins, Th17: effector lymphocyte T, Treg: regulatory lymphocyte T, IFN-α: type I interferon, ROS: radical oxygen species, Ig: immunoglobulin, TGF-β: transforming growth factor-β; n.a.= data not available.